The state of Illinois has announced that it will delay awarding 75 licenses for new marijuana dispensaries due to the coronavirus crisis. It joins the number of states who have had marijuana initiatives, from legalization to licensing, disrupted by the outbreak.

On Wednesday last week, the Illinois Department of Financial and Professional Regulation, which regulates dispensaries, announced that it will not award the 75 licenses until Governor J.B. Pritzker’s disaster proclamations end or the state decides on another date.

The governor is expected to sign a new order extending the state’s disaster proclamation through May 30.

Although recreational marijuana sales started on Jan 1, only existing operators were allowed to participate. The state has about 50 dispensaries selling recreational marijuana, and the delay will grant them monopoly status over the state’s mammoth marijuana market. Customers in Illinois spent around $110.2 million on legal cannabis within the first three months of sales.

The 75 Conditional Adult-Use Cannabis Dispensing Organization Licenses were set to be awarded by May 1 but it is now unclear how long the applicants will have to wait. There were more than 700 applications for the 75 available licenses, and many of them were social equity applicants.

These are individuals who have a marijuana-related arrest on their record, live in an area that’s been disproportionately hit by the war on drugs, or meets another qualifier. According to Too Hutchinson, senior adviser to the governor on cannabis control, the Pritzker administration is committed to creating a marijuana industry that reflects the diversity of Illinois residents.

“We recognize that countless entrepreneurs were looking forward to May 1 and the next step it represented for Illinois’s adult-use cannabis industry. However, the ongoing COVID-19 situation has caused delays in this application review process. This executive order will help ensure that we continue to build out this industry in a deliberate and equity centric manner,” she said in a statement.

The applicants who eventually win licenses will be granted 180 days to source a location if they haven’t already. The location will have to be inspected by the state before any commerce can begin.

According to the Chicago Tribune, licenses offer the first path into Illinois’ burgeoning marijuana industry for people who didn’t already operate a cannabis facility. The state would get an influx of tax revenue from increased sales to help cushion it against the pandemic’s economic fallout as well as provide much-needed employment opportunities.

Analysts believe members of the cannabis industry, such as Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), will be disappointed that their aspiring counterparts in Illinois will have to wait for an unknown duration before they can get a go-ahead to start dispensary operations.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced it has advanced its North American new clinical entity (“NCE”) expansion stratagem via the formation of a dedicated planning committee (the “Committee”). “We will look to capitalize on the fragmented nature of the U.S. ketamine clinic marketplace with the objective of creating a consortium of integrated mood disorder treatment and research facilities,” Gareth Birdsall, CEO of Champignon, said in the news release. “By leveraging existing protocols, data sets and SOPs from our flagship clinic, the Canadian Rapid Treatment Centre of Excellence, arguably the most advanced integrated mood disorder centre in North America, we will improve economics, increase patient enrollment and function as the pre-eminent brick and mortar staging ground for novel molecule discovery initiatives. Champignon remains bullish on the U.S. marketplace due to favourable co-payer infrastructure, as well as a vast addressable patient population.”

To view the full press release, visit http://cnw.fm/Rns1B

About Champignon Brands Inc.

Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

The economic fallout from the coronavirus crisis will be massive. With the U.S. already sliding into a recession, experts say it may take years for Americans to recover financially. With the economy in such a state, would it be wise to invest? Wouldn’t it be better to hold onto those funds and see how things play out?

Well, it depends on what you’re investing in. Some stocks, like airline and restaurant stocks, aren’t doing so well right now. A whole lot of industries have been affected by the outbreak, with most of the new unemployment cases concentrated in a certain group of sectors. Cannabis, on the other hand, seems to be holding up.

Most states with legal cannabis programs deemed the cannabis sector essential, meaning cannabis shops and dispensaries could continue operating during the lockdown. Extra measures such as curbside pickups and home deliveries are being approved to make sure their operations remain safe and hygienic. This already gives the cannabis sector an edge over the scores of industries that have been affected by the coronavirus.

However, the fact that cannabis is considered a ‘vice industry’ has made some experts wonder whether it is recession-proof. Historically, vice industries like alcohol have enjoyed increased sales in times of great stress. After most states issued their stay at home orders, cannabis stores reported a spike in demand, with some stating they had lines longer than the ones on the unofficial cannabis holiday 4/20.

The fact that cannabis is medicinal also works in its favor. There are over 200 million registered medical marijuana patients in the country, and with the industry still running, they are still purchasing cannabis. The plant is also a good anti-anxiety drug, and we can agree that this is an extremely stressful time. Both recreational and medical users can use it to help reduce their anxiety and stress.

The coronavirus crisis may even be a blessing in disguise for the cannabis industry. The fact that most states with legal cannabis have deemed it essential has proved that the industry is vital. Hundreds of thousands of employees and millions of patients rely on it, after all. On top of that, it can provide much-needed tax revenue.

The state of Illinois, for instance, has tapped into an emergency relief fund that was funded by cannabis sales taxes to help cushion rural pharmacies during the crisis. This proves just how valuable a legal cannabis market can be, making it an attractive option for investment.

Analysts therefore predict that investors who enter the industry now may reap big in future when the industry players, such as Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), soar even higher in the years to come.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) continues to strengthen its vertically integrated psychedelic medicine ecosystem via the acceleration of its ketamine topicals prescription fulfillment capabilities. The company today announced the addition of central fill and compounding infrastructure for its proprietary ketamine formulations via a location at one of Canada’s leading retail pharmacy chains (the “Pharmacy”), as well as the dispensing of its products throughout the Pharmacy’s network. “With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies,” Champignon CEO Gareth Birdsall stated in the news release. “From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle.”

In addition, Champignon announced the closing of its acquisition of AltMed Capital Corp., subject to the submission of the necessary filings to the BC Corporate Registry and including any other necessary regulatory approvals. AltMed is a Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer with a suite of assets that will accelerate Champignon’s multipronged business strategy. This will enable the company to reach the consumer directly through rapid-onset medical treatments, with an anticipated rollout of already identified new clinical entities (“NCEs”) to be opened across the United States and Canada.

To view the full press release, visit http://cnw.fm/2r6Sp

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced that it has been chosen as the Headline Partner for Prohibition Partners LIVE’s PSYCH: The Psychedelics Symposium (“PSYCH”). The psychedelics virtual conference, scheduled to take place June 22 – 23, 2020, will highlight the most recent developments in the psychedelic industry, hear from world-renowned speakers and engage with a network of industry-leading professionals. “The impact of COVID-19 has put greater emphasis on the importance of mental health. Consumers are looking for options to improve their mental health and, as the body of evidence mounts for psychedelics, the healthcare industry is responding with solutions. We’re delighted to partner with Champignon Brands on PSYCH and support their vision of improving mental health via psychedelics,” Prohibition Partners Managing Director Stephen Murphy stated in the news release.

To view the full press release, visit http://cnw.fm/diOU8

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

With the coronavirus sweeping through the world, most of us have been indoors for quite a while. And as experts have said, we might be stuck with the virus for the foreseeable future, so our time inside might drag on even longer. Bad as it sounds, it is the best way to completely eradicate the virus.

However, humans aren’t meant to be sedentary creatures. Chances are you’re spending a large portion of the day seated in front of a computer screen. And I bet you’re not paying attention to your posture. Doing that for extended periods of time will definitely lead to aches and pains, especially to your back.

On top of that, this is a very stressful time. Vacation time doesn’t usually coincide with the outbreak of a life threatening virus, and nerves are understandably frayed right now. It gets easy to fall out of exercise, healthy eating routines and mess up your normal sleep cycle. This, coupled with the stress and anxiety caused by the pandemic can weaken your immune system, putting you at greater risk of succumbing to the virus.

So how can CBD help you treat your pains and stay in top shape during the lockdown? Well, CBD is a powerful pain reliever and according to Gallup, 40% of American CBD users use it for pain relief. Studies have found that it is effective at alleviating different kinds of pain, including cancer pain, neuropathic pain and fibromyalgia.

Topical CBD applications offer the quickest pain relief, but ingestible options like oils also work. It will take a while for the effects to kick in, though. For sore muscles and joints from sitting down for long hours, CBD topical oils and creams would be the best option. If you’ve been working out and you are feeling a little sore afterward, they will help ease the soreness and aid your recovery.

For more chronic or localized, recurring pain, you’d be better off with ingestible CBD products. Cannabidiol interacts with a peripheral nervous system called the endocannabinoid system (ECS), resulting in anti-inflammatory and pain relieving effects.

However, CBD isn’t a magic cure. Try and do some exercise everyday as it has been found to boost immunity. Mix in a little yoga to help stretch out your muscles and remove any knots that may form after long hours of inactivity. On top of that, make sure you eat healthy foods during the duration of the lockdown.

Experts advise that people read the product information availed on products by manufacturers like Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) so that consumers can reap maximum benefits from the different cannabidiol products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced that its common shares have graduated from the OTC Pink Open Market to the OTCQB Venture Market (the “OTCQB”), a U.S. trading platform operated by the OTC Markets Group. Effective immediately, Champignon Brands will commence trading on the OTCQB under the ticker symbol “SHRMF.” Champignon’s common shares will continue to trade under the ticker symbol “SHRM” on the Canadian Securities Exchange as well as under the ticker symbol “496” on the quotation board of the Frankfurt Stock Exchange.

To view the full press release, visit http://cnw.fm/i36Vq

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

2020 would have been a historic year for marijuana lovers. 4/20 has always been the unofficial holiday for marijuana, and if you think about it, the entire month of April would have been 4/20. However, the Coronavirus pandemic has left the world in a health and economic crisis, and most companies and marijuana shops were forced to downgrade their 4/20 plans or scrap them entirely.

However, thanks to the internet, not everything was lost. The web has already been a great help as people practice social distancing and self-isolation, and marijuana enthusiasts used it to celebrate 4/20.

“Celebrating 4/20 means smoking a lot of weed, and luckily we all are able to do it right now if we’ve got our hands on a stash. April 20 is like our Saint Patrick’s Day. Instead of going out and drinking, we smoke,” says 25-year-old cannabis influencer Koala Puffs.

As more states launch medical and recreational marijuana programs and marijuana becomes more accepted, 4/20 has been widely embraced in mainstream culture. From cannabis companies and shops to the everyday stoner, everyone who is part of cannabis culture sets the day aside for something special.

For Koala Puffs, the day is pretty eventful. The cannabis influencer has nearly 250,000 YouTube subscribers and over 700,000 Instagram followers. On D-Day, she did giveaways on Instagram and Twitter every hour, on top of doing Zoom hangouts and live streaming on Instagram.

For someone who built her fan base by interacting with other stoners, we couldn’t have expected any less. And in the spirit of social distancing, she hosted a smoke session before the digital Vimeo debut of a film dubbed 4/20. The ensemble stoner comedy about the aforementioned holiday is her feature film debut.

“The movie is not your usual stoner movie where everybody is baked the entire time, on a stone adventure. In this movie, there are different types of stoners, from the ones who smoke every day to me and my crew, who can’t get our hands on any because we’re underage,” she says.

Cannabis was lucky enough to be declared essential in most states with legal weed and has been seeing increased demand and sales during the crisis. According to Kate Miller, co-founder of Miss Grass, an online cannabis magazine and e-commerce platform, true stoners who have been consuming the plant for a long time are probably consuming it more than normal given they’re all home.

“But I also think there’s an opportunity for new consumers. In California and other states where there’s a regulated cannabis program, it’s considered an essential business during this pandemic. It’s easier for me to get weed right now than it is to get toilet paper.”

How did established sector players like Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) tweak their 4/20 plans? Analysts can only guess for now.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company that is advancing its clinical pipeline through its ongoing TBI/PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine, today announced that its research partner and lead investigator, Dr. Michael Hoffer, has obtained a sustainable supply of psilocybin under a DEA schedule I license, which will be used for ongoing psilocybin-based therapeutics studies. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, Champignon’s wholly owned subsidiary, Tassili Life Sciences Corp., is conducting preclinical studies and eventual human clinical trials, with the intention of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. “We hope to continue to make significant progress on our preclinical trial studying the effects of an oral combination of psilocybin and CBD on mTBI associated with PTSD,” Champignon Brands research partner and lead investigator Dr. Michael Hoffer stated in the news release. “Since mTBI associated with PTSD is a combination disorder that affects more than 10 million individuals per year and has no proven medical treatment, our novel combination of medicines could be a breakthrough in treating these indications.”

To view the full press release, visit http://cnw.fm/0PzWo

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

The effects of the Coronavirus pandemic will likely be felt for years to come. Experts say the virus may end up infecting up to 70% of the world’s population, and we may need to have sporadic lockdowns till 2022 to completely eradicate it. It’s safe to say that shutting down most businesses and essentially slowing down consumer spending has had a catastrophic effect on the economy.

With most industries feeling the strain, a lot of businesses have had to let some of their staff go. A record 6 million people filed for unemployment, raising the number of unemployed Americans filing for aid to a whopping 22 million. However, some sectors have thrived amid all the chaos, such as cannabis. Deemed an essential industry by most states that allow marijuana, cannabis businesses have been able to operate unabated during the Coronavirus crisis.

However, cannabis firms in Pennsylvania have run into roadblocks while trying to employ new ‘bud-tenders,’ the staffers who consult with patients. This is despite the fact that more than one in six Pennsylvanians has filed for unemployment since the Coronavirus shutdowns began.

Prospective employees require FBI background checks and drug tests, but most of the offices that process fingerprints are shut down for the time being. “It’s just so unbelievably frustrating. I have five clients with over 100 openings, and there are likely hundreds more that are waiting. These are good-paying jobs, many of which come with health care benefits,” says Harrisburg lawyer Judith Cassel.

She sent a letter to the state Department of Health, requesting a temporary 90-day waiver that would allow job candidates to sign an affidavit stating they don’t have a criminal record. They would also undergo third-party background checks, and any untruthful responses or failing the test will result in immediate termination.

Cassel stressed on the fact that although these measures were indeed useful, these are special times and they require special solutions. “We understand the need for background checks and department oversight on hires during normal circumstances, but these are not normal times. The current process does not rise to the current challenge.”

This problem isn’t restricted to Pennsylvania only. According to an official with Chicago-based marijuana company Cresco Labs, the firm has had a hard time finding people to fill 250 workers in Illinois.

“Under normal circumstances, it would take two to six weeks to get approved,” says Cresco’s Executive Vice President John Sullivan. “But since most state government functions are closed down and a lot of the fingerprint agencies shut, too, the process is stretching out longer and longer.”

Experts believe that cannabis firms like Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) are frustrated that at a time when jobs are being lost, an industry that can employ more people is being held back by a freeze on crucial processes that are a prerequisite for people to secure the available jobs.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.